Resolution of The II International Menopause Expert Forum




resolution, Ukrainian Society of Gynecological Endocrinology, International Menopause Expert Forum, menopausal hormonal treatment


The II International Menopause Expert Forum was held on November 20, 2020. The working group included leading specialists in gynecological endocrinology from Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Uzbekistan and Ukraine. The experts addressed issues related to the early onset of menopausal hormone treatment (MHT), the safety profile of MHT on the breast, and developed algorithms for managing unscheduled bleeding in women taking MHT.
Currently, there is also convincing evidence of comprehensive benefits of timely initiation of MHT – during the “window of opportunity” (in women under the age of 60 or earlier than 10 years after the menopause).
Personalized approach to the treatment of each patient is a priority when choosing the treatment tactics for menopausal symptoms. The lower dose of estrogen is preferred at the beginning of treatment, cyclic combined regimen is preferred in perimenopause and continuous combined regimen in postmenopause. MHT requires periodic dosage adjustments depending on the stage of reproductive aging, age, treatment efficacy and tolerability.
The incidence of bleeding on MHT is up to 77% when cyclic regimen is used and up to 40% with continuous regimen. As a result, up to 50% of women stop MHT, so proper management is critical. The key issues clinicians need to address are to rule-out endometrial cancer and establish the cause of hemorrhage; there can be multiple causes of unscheduled bleeding but they are often benign. The management should be rational and does not require the discontinuation of MHT if there are no endometrial pathology or significant risk factors.
Breast cancer risk associated with MHT often becomes the cornerstone when prescribing medication. Hormonal therapy with a gestogenic component makes the greatest contribution to the risk of breast cancer. Studies have shown that progesterone and dydrogesterone in MHT are not associated with an increased risk of breast cancer, but synthetic progestogens are associated. The risk minimization activities include taking history, evaluation of breast status, informing patients and choosing the right MHT components.


  1. [online resource]. World Demographics. Available from: [https://www.], last accessed 20 Jan 2021.
  2. Ulumbekova, G.E., Khudova, I.Y. “Assessment of the demographic, social and economic effect when taking menopausal hormonal therapy.” ORGZDRAV: news, opinions, training. Bulletin of VSHOUZ 6.4 (2020): 23–53. DOI: 10.24411/2411-8621-2020-14002
  3. Turner, R.J., Kerber, I.J. “Eu-estrogenemia, WHI, timing and the "Geripause".” Int Urogynecol J Pelvic Floor Dysfunct 19 (2008): 1461–3.
  4. Yureneva, S.V., Dubrovina, A.V. “Advantages of early and timely start of menopausal hormone therapy from the standpoint of the theory of estrogenesis.” Russian Bulletin of Obstetrician-Gynecologist 18.5 (2018): 49–55.
  5. Hodis, H.N., Mack, W.J., Shoupe, D., et al. “Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.” Menopause 22.4 (2015): 391–401. DOI: 10.1097/GME.0000000000000343
  6. Bild, D.E., Bluemke, D.A., Burke, G.L., et al. “Multi-Ethnic Study of Atherosclerosis: objectives and design.” American Journal of Epidemiology 156.9 (2002): 871–81. DOI: 10.1093/aje/kwf113
  7. Boardman, H.M.P., et al. “Hormone therapy for preventing cardiovascular disease in post-menopausal women.” Cochrane Database Syst Rev 3 (2015): CD002229.
  8. Nappi, R.E., Simoncini, T. “Menopausal transition: a golden age to prevent cardiovascular disease”. The Lancet 9.3 (2021): 135–7. DOI: 10.1016/S2213-8587(21)00018-8
  9. Manson, J.E., Chlebowski, R.T., Stefanick, M.L., et al. “Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials.” JAMA 310 (2013): 1353–68.
  10. Roehm, E. “A reappraisal of Women’s Health Initiative Estrogen-Alone Trial: long-term outcomes in women 50–59 years of age.” Obstet Gynecol Int 2015 (2015): 713295.
  11. Panay, N., et al. “Premature ovarian insufficiency: an International Menopause Society White Paper.” Climacteric 23.5 (2020): 426–46. DOI: 10.1080/13697137.2020.1804547
  12. Baber, R.J., Panay, N., Fenton, A.; the IMS Writing Group. “IMS Recommendations on women’s midlife health and menopause hormone therapy.” Climacteric 19.2 (2016):109–50.
  13. Resolution of the I International Forum of Experts on Menopause. Reproductive Endocrinology 1.51 (2020): 8–12.
  14. Fife NHS Board Area Drugs and Therapeutics Committee [online resource]. Guidance on management of the menopause in primary care. Available from: [], last accessed Sep 13, 2021.
  15. The North American Menopause Society. “The 2017 hormone therapy position statement of The North American Menopause Society.” Menopause 24.7 (2017): 728–53.
  16. Tsiligiannis, S., et al. “Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms.” Maturitas (2020).
  17. Thomas, A.M., Hickey, M., Fraser, I.S. “Disturbances of endometrial bleeding with hormonereplacement therapy.” Human Reproduction 15 Suppl. 3 (2000): 7–17.
  18. Dave, F.G., et al. “Unscheduled bleeding with hormone replacement therapy.” The Obstetrician & Gynaecologist 21.2 (2019): 95–101.
  19. Clarke, M.A., Long, B.J., Del Mar Morillo, A., et al. “Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis.” JAMA Intern Med 178.9 (2018): 1210–22. DOI: 10.1001/jamainternmed.2018.2820
  20. Bengtsen, M.B., Veres, K., Norgaard, M. “First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.” Br J Cancer 122.3 (2020): 445–51. DOI: 10.1038/s41416-019-0668-2
  21. Carugno, J. “Clinical management of vaginal bleeding in postmenopausal women.” Climacteric 23.4 (2020): 343–9. DOI: 10.1080/13697137.2020.1739642.
  22. Lou, Y.Y., et al. “Unscheduled bleeding on HRT - do we always need to investigate for endometrial pathology?” Int J Reprod Contracept Obstet Gynecol 6.10 (2017): 4174–8. DOI: 10.18203/2320-1770.ijrcog20174391
  23. de Medeiros, S.F., Yamamoto, M.M., Barbosa, J.S. “Abnormal bleeding during menopause hormone therapy: insights for clinical management.” Clin Med Insights Womens Health 6 (2013): 13–24. DOI: 10.4137/CMWH.S10483
  24. Crawford, S.L., Crandall, C.J., Derby, C.A., et al. “Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results.” Menopause 26.6 (2018): 588–97. DOI: 10.1097/GME.0000000000001282
  25. Chlebowski, R.R., Anderson, G.G. “Changing Concepts: Menopausal Hormone Therapy and Breast Cancer.” J Natl Cancer Inst 104 (2012): 517–27. DOI: 10.1093/jnci/djs014
  26. Hersh, A.A., Stefanick, M.M., Stafford, R.R. “National use of menopausal hormone therapy: Annual trends and response to recent evidence.” JAMA 291 (2004): 47–53. DOI: 10.1001/jama.291.1.47
  27. Chlebowski, R.T., Anderson, G.L., Aragaki, A.K., et al. “Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.” JAMA 324.4 (2020): 369–80. DOI: 10.1001/jama.2020.9482
  28. Fournier, A., et al. “Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.” Breast Cancer Res Treat 107 (2008): 103–11.
  29. Cordina-Duverger, E., et al. “Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.” PLoS One 8 (2013): e78016.
  30. Lyytinen, H., et al. “Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.” Obstet Gynecol 113 (2009): 65–73.
  31. Vinogradova, Y., Coupland, C., Hippisley-Cox, J. “Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.” BMJ 371 (2020): m3873.
  32. Данные Морион, Rx test, Q4 2019 –Q3 2020, ATC G3F, G3C
  33. Medical eligibility criteria for contraceptive use, 5th ed. Geneva. World Health Organization (2015).
  34. Australian Menopause Society [online resource]. Early menopause. Available from: [ au/hp/management/early-menopause], last accessed Sep 13. 2021.
  35. British Menopause Society [online resource]. The NICE guideline: diagnosis and management of the menopause (2015). Available from: [], last accessed Sep 13. 2021.
  36. Anagnostis, P., et al. “Menopause symptom management in women with dyslipidemias: an EMAS clinical guide.” Maturitas (2020).
  37. Slopiena, R., et al. “Menopause and diabetes: EMAS clinical guide.” Maturitas 117 (2018): 6–10.
  38. Kuh, D., Cooper, R., Moore, A., et al. “Age at menopause and lifetime cognition: Findings from a British birth cohort study.” Neurology 90.19 (2018): e1673-e1681. DOI: 10.1212/WNL.0000000000005486
  39. de Villiers, T.J., Gass, M.L., Haines, C.J., et al. “Global consensus statement on menopausal hormone therapy.” Climacteric 16.2 (2013): 203–4. DOI: 10.3109/13697137.2013.771520
  40. Telli, M.L., Gradishar, W.J., Ward, J.H. “NCCN Guidelines Updates: Breast Cancer.” J Natl Compr Canc Netw 17.5.5 (2019): 552–5. DOI: 10.6004/jnccn.2019.5006
  41. Miller, V.M., Kling, J.M., Files, J.A., et al. “What’s in a name: are menopausal ‘hot flashes’ a symptom of menopause or a manifestation of neurovascular dysregulation?” Menopause 25.6 (2018): 700–3.
  42. Tepper, P.G., Brooks, M.M., Randolph, J.F. Jr, et al. “Characterizing the trajectories of vasomotor symptoms across the menopausal transition.” Menopause 23 (2016): 1067–74.
  43. Clarkson, T.B. “NAMS endowed lecture – estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression.” Menopause 14 (2007): 373–84.
  44. Lou, Y.Y., et al. “Unscheduled bleeding on HRT - do we always need to investigate for endometrial pathology?” Int J Reprod Contracept Obstet Gynecol 6.10 (2017): 4174–8. DOI: 10.18203/2320-1770.ijrcog20174391
  45. Ettinger, B. “Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy.” Obstet Gynecol 102.6 (2003): 1225–32. DOI: 10.1016/j.obstetgynecol.2003.08.007
  46. Crawford, S.L., Crandall, C.J., Derby, C.A., et al. “Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results.” Menopause 26.6 (2018): 588–97. DOI: 10.1097/GME.0000000000001282
  47. Torrens, J.I., Sutton-Tyrrell, K., Zhao, X., et al. “Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in mid-life women.” Menopause 16 (2009): 257–64.
  48. Markopoulos, M.C., Kassi, E., Alexandraki, K.I., et al. “Hyperandrogenism after menopause.” Eur J Endocrinol 172.2 (2015): R79–91. DOI: 10.1530/EJE-14-0468
  49. Wierman, M.E., Arlt, W., Basson, R., et al. “Androgen therapy in women: A reappraisal: An Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab 99 (2014): 3489–3510.



How to Cite

-, .-. (2021). Resolution of The II International Menopause Expert Forum. REPRODUCTIVE ENDOCRINOLOGY, (60), 77–84.



Health care